At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 106 enrolled
Drug / intervention
glepaglutide +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 3, International, Multicenter, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy and Safety of Glepaglutide in Patients With Short Bowel Syndrome (SBS)
In Brief
A Phase 3 clinical trial evaluating glepaglutide and Placebo for Short Bowel Syndrome. Completed, enrolled 106 participants across 29 sites in 9 countries.
Detailed Summary
The primary objective of the trial is to confirm the efficacy of glepaglutide in reducing parenteral support volume in patients with short bowel syndrome. Glepaglutide is the International Nonproprietary Name and USAN for ZP1848.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsShort Bowel Syndrome
CountriesBelgium, Canada, Denmark, France, Germany, Netherlands, Poland, United Kingdom, United States
Collaborators--
Timeline
Phase 3CompletedFinished
20192020202120222023202420252026
First PostedOct 2018
Enrollment StartOct 2018
Primary CompletionJul 2022
TodayJul 2026
First PostedOct 1, 2018
Enrollment StartOct 4, 2018
Primary CompletionJul 26, 2022
TodayJul 2, 2026
Enrollment to primary: 3.8 yearsPosted 7.8 years ago
Interventions
glepaglutidedrug
Glucagon-Like Peptide-2 (GLP-2) analog
Placebodrug
Placebo for glepaglutide